NEW YORK, NY
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)INTERNATIONAL AIDS VACCINE INITIATIVE INC, founded in 1996, is a major nonprofit in the International Affairs sector that reported $129.7M in total revenue in fiscal year 2023. Revenue decreased 12% compared to the prior year.
A NONPROFIT SCIENTIFIC RESEARCH ORGANIZATION THAT DEVELOPS VACCINES AND ANTIBODIES FOR HIV, TUBERCULOSIS, EMERGING INFECTIOUS DISEASES, AND NEGLECTED DISEASES.
RESEARCH AND DEVELOPMENT: THROUGH SCIENTIFIC AND CLINICAL RESEARCH IN AFRICA, INDIA, EUROPE, AND THE U.S., IAVI DEVELOPS VACCINES AND ANTIBODIES IN AND FOR THE DEVELOPING WORLD AND SEEKS TO...
RESEARCH AND DEVELOPMENT: THROUGH SCIENTIFIC AND CLINICAL RESEARCH IN AFRICA, INDIA, EUROPE, AND THE U.S., IAVI DEVELOPS VACCINES AND ANTIBODIES IN AND FOR THE DEVELOPING WORLD AND SEEKS TO ACCELERATE THEIR INTRODUCTION IN LOW-INCOME COUNTRIES. IAVI ADVANCES SCIENTIFIC DISCOVERY AND DEVELOPMENT BY FOSTERING UNIQUE COLLABORATIONS AMONG ACADEMIA, INDUSTRY, LOCAL COMMUNITIES, GOVERNMENTS, AND FUNDERS TO EXPLORE NEW AND BETTER WAYS TO ADDRESS PUBLIC HEALTH THREATS THAT DISPROPORTIONATELY AFFECT PEOPLE LIVING IN POVERTY. VACCINE AND ANTIBODY CANDIDATES ARE PUT THROUGH A RIGOROUS PROCESS OF CLINICAL EVALUATION AMONG KEY POPULATIONS TO ESTABLISH THEIR SAFETY AND EFFICACY, AN EFFORT THAT ENABLES IAVI TO STRENGTHEN THE HEALTHCARE INFRASTRUCTURE AND SCIENTIFIC CAPACITY OF COUNTRIES WHERE OUR CLINICAL PARTNERS OPERATE. TO DATE, IAVI AND ITS PARTNERS HAVE ADVANCED DOZENS OF HIV VACCINE CANDIDATES INTO EARLY STAGE CLINICAL TRIALS, INCLUDING A VACCINE THAT RECENTLY YIELDED PROMISING RESULTS AND IS PART OF AN EXCITING NEW APPROACH TO HIV VACCINE DESIGN. OTHER NOTABLE ACHIEVEMENTS INCLUDE THE FIRST HIV VACCINE TRIALS IN SUB-SAHARAN COUNTRIES, WHERE HIV BURDEN IS GREATEST, AND THE FIRST TRIAL OF AN MRNA HIV VACCINE CANDIDATE IN AFRICA. IAVI HAS CONDUCTED MORE THAN 50 EPIDEMIOLOGICAL STUDIES AND PROVIDED VOLUNTARY HIV TESTING, COUNSELING SERVICES, AND HEALTH CARE REFERRALS TO MORE THAN 870,000 INDIVIDUALS IN AFRICA. IAVI ALSO SUPPORTS PRECLINICAL DEVELOPMENT AND CLINICAL TESTING OF VACCINE CANDIDATES FOR OTHER DISEASES, INCLUDING TUBERCULOSIS, LASSA FEVER, MARBURG, EBOLA SUDEN, AND COVID-19, AS WELL AS ANTIBODY CANDIDATES FOR DISEASE PREVENTION AND TREATMENT. IAVI CONDUCTS TRIALS WITH THE HIGHEST SCIENTIFIC AND ETHICAL STANDARDS TO PROTECT THE RIGHTS, WELL-BEING, AND DIGNITY OF TRIAL VOLUNTEERS. IAVI HAS ALSO LAUNCHED RESEARCH CONSORTIA TO ADDRESS MAJOR SCIENTIFIC PROBLEMS OF BIOMEDICAL PRODUCT DEVELOPMENT. A SIGNIFICANT PORTION OF THE RESEARCH IAVI SUPPORTS IS CONDUCTED IN DEVELOPING COUNTRIES WHERE THE NEED FOR INFECTIOUS DISEASE PREVENTION IS GREATEST. IAVI ALSO SUPPORTS EXTERNAL RESEARCHERS BY PROVIDING TECHNICAL AND SCIENTIFIC EXPERTISE TO ACCELERATE THE DEVELOPMENT OF THEIR OWN PRODUCTS.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $129,678,400 | $146,782,280 | -0.1% |
| Expenses | $132,896,237 | $131,188,762 | +0.0% |
| Net Income | $-3,217,837 | $15,593,518 | -1.2% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| MARK B FEINBERG | PRESIDENT/CEO | 35.00 |
Officer
Director
|
$719,151 | $110,715 | $829,866 |
| ERIC PAUL GOOSBY | BOARD CHAIR | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| ROBERT GOLDBERG | BOARD TREASURER | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| LINDA-GAIL BECKER | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| DAVID BLUMBERG | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| JIM CONNOLLY | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| MARK DYBUL | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| WAFAA EL-SADR | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| ALEXIS M PINTO | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| JOHN W SHIVER | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| SUSAN SILBERMANN | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| ANNE MARTIN SIMONDS | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| RAJEEV VENKAYYA | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| MARIJKE WIJNROKS | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| ANA CESPEDES MONTOYA | CHIEF OPERATING OFFICER | 35.00 |
Officer
|
$531,087 | $79,268 | $610,355 |
| LOUIS D SCHWARTZ | ASST. SEC. & CFAO | 35.00 |
Officer
|
$390,586 | $76,520 | $467,106 |
| MIN DING | GEN. COUNS. & SEC. | 35.00 |
Officer
|
$333,986 | $71,843 | $405,829 |
| MARIO GAGLIANO | CPO, VP OF HR (FROM 9/23) | 35.00 |
Officer
|
$102,045 | $14,230 | $116,275 |
| SWATI GUPTA | VP, HEAD OF EID & EPIDEM. | 35.00 |
Highest
|
$379,201 | $76,490 | $455,691 |
| DAGNA LAUFER | VP & HEAD OF CLINICAL DEV. | 35.00 |
Highest
|
$394,188 | $41,148 | $435,336 |
| CHRISTOPHER PARKS - ASSOC | AVP. VIRAL VAC. & HEAD OF DDL | 35.00 |
Highest
|
$365,204 | $62,119 | $427,323 |
| ERIC SKJEVELAND | VP, BUSINESS DEVELOPMENT | 35.00 |
Highest
|
$341,395 | $36,715 | $378,110 |
| SANGEETHA SAGAR | VP & HEAD OF PRODUCT DEV | 35.00 |
Highest
|
$376,047 | $33,504 | $409,551 |
| FRANCES SINHA | FORMER OFFICER | 35.00 |
|
$105,000 | $0 | $105,000 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | No data | No data | No data | No data |
| 2023 | $129,678,400 | $132,896,237 | $124,233,943 | $-3,217,837 |
| 2022 | $146,782,280 | $131,188,762 | $128,948,484 | $15,593,518 |
| 2021 | $126,352,598 | $113,151,683 | $107,049,023 | $13,200,915 |
| 2020 | $97,111,665 | $96,068,184 | $81,721,759 | $1,043,481 |
| 2019 | $88,458,944 | $87,783,507 | $74,755,062 | $675,437 |
| 2018 | $77,192,773 | $83,383,050 | $83,382,669 | $-6,190,277 |
Compare INTERNATIONAL AIDS VACCINE INITIATIVE INC with other nonprofits in New York and across the country.